Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

Importance Evidence of the clinical benefit of pharmacogenetics-informed treatment (PIT)
with antidepressants is still limited. Especially for tricyclic antidepressants (TCAs) …

Psychotropic medication efficacy and tolerability are critical treatment issues faced by
individuals with psychiatric disorders and their healthcare providers. For some people, it can …

Background: Pharmacogenomic testing to identify variations in genes that influence
metabolism of antidepressant medications can enhance efficacy and reduce adverse effects …

Objectives With increasing evidence for the clinical utility of pharmacogenomic (PGx) testing
for depression, there is a growing need to consider issues related to the clinical …

With the trend towards promoting personalised medicine (PM), the application of
pharmacogenetics and pharmacogenomics (PGx) is of growing importance. For the …

This systematic review evaluated the animal and human evidence for
pharmacomicrobiomics (PMx) interactions of antidepressant medications. Studies of gut …

Aim To determine the efficacy and safety of pharmacogenomics (PGx)-guided
antidepressant prescribing in patients with depression through an umbrella review and …

Objective: In this review, the authors update the 2018 report of the American Psychiatric
Association Council of Research Workgroup on Biomarkers and Novel Treatments on …